Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners
Antiphospholipid syndrome, or APS, is one of the most common acquired causes of blood clots in young people, yet it remains widely misunderstood and under-recognized. It is an autoimmune condition in which specific antibodies, particularly those targeting a protein called beta-2 glycoprotein I (beta2GPI), do far more than serve as disease markers. These antibodies actively drive the development of clots in both veins and arteries, can cause repeated pregnancy losses, and may damage the small blood vessels supplying the heart, kidneys, and other organs. The condition can also cause a drop in platelet count and affect cardiac valves. In its most severe form, catastrophic APS (or CAPS), clotting occurs simultaneously in multiple organs and carries a high mortality rate.
A new review published in Arthritis & Rheumatology, covered in a report by The Rheumatologist in August 2025, frames APS as fundamentally an antibody-mediated disease. The authors, Jason S. Knight, MD, PhD, of the University of Michigan Medical School, and Thalia G. Newman, BS, a PhD candidate in Dr. Knight's lab, argue that this framing matters because it changes how rheumatologists should think about treatment. "APS is a condition in which antibodies are not just markers of disease but also drive pathogenesis," Dr. Knight explained. As rheumatologists become familiar with targeted therapies developed for other antibody-mediated conditions, such as myasthenia gravis and immune thrombocytopenia, it becomes reasonable to ask whether similar approaches might work in APS.
Right now, the standard treatment for APS is anticoagulation, typically with warfarin, which reduces the risk of clots but does not address the underlying autoimmune process. That means patients remain at risk for breakthrough events and must manage the burdens of lifelong anticoagulation, including regular blood monitoring and dietary restrictions. The review outlines a pipeline of investigational agents that aim to target the disease at its source: the plasma cells and B cells producing pathogenic antibodies.
Clinical trials listed in the review are actively recruiting patients for a range of agents, including zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor; telitacicept, both alone and in combination with rituximab; an anti-CD38 monoclonal antibody; anti-CD19 chimeric antigen receptor (CAR) T cells; anti-CD19 CAR-natural killer (NK) cells; belimumab; and a combined anti-BCMA/CD19 CAR T cell approach. The diversity of this pipeline reflects growing momentum toward immunomodulation as a treatment strategy for APS, not just clot prevention.
The review also provides a detailed breakdown of how anti-beta2GPI IgG antibodies activate pro-thrombotic cells, giving readers a clearer picture of why these antibodies cause such varied and serious harm. For patients who have struggled with recurrent clots, pregnancy complications, or relapsing disease despite anticoagulation, the emergence of these trials represents a meaningful development. While none of these therapies are yet approved for APS, the authors express optimism that the next phase of research will finally allow treatment of the disease at its autoantibody-mediated source.
Source: The Rheumatologist, August 6, 2025. Based on a review by Jason S. Knight, MD, PhD and Thalia G. Newman, BS, published in Arthritis & Rheumatology. URL: https://www.the-rheumatologist.org/article/emerging-therapies-for-antiphospholipid-syndrome-an-antibody-mediated-disease/
Disclaimer: This summary is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.